Price T Rowe Associates Inc Entrada Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,903,025 shares of TRDA stock, worth $35.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,903,025
Previous 3,049,572
4.81%
Holding current value
$35.2 Million
Previous $48.7 Million
3.0%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding TRDA
# of Institutions
104Shares Held
28.9MCall Options Held
40.3KPut Options Held
4.1K-
Baker Bros. Advisors LP New York, NY4.87MShares$59 Million0.93% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$53.4 Million33.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$53.1 Million60.89% of portfolio
-
Janus Henderson Group PLC London, X02.08MShares$25.2 Million0.02% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$20.5 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $380M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...